Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Feb 21, 2024
Distillery Therapeutics
Inhibiting ETS1 or RBPJ in T cell therapies for cancer
BioCentury | Dec 19, 2022
Product Development
Arcus’ TIGIT data don’t provide hoped for differentiation
Domvanalimab/PD-1 combo doesn’t stack up to Roche combo, which missed Phase III endpoint
BioCentury | Nov 24, 2020
Deals
OncoImmune's choice to repurpose GvHD program for COVID pays off via $425M takeout by Merck
OncoImmune’s move to repurpose its GvHD program for COVID-19 has paid off via a takeout by Merck for $425 million up front. Under the deal, which includes undisclosed milestones and royalties,
BioCentury | Jan 25, 2020
Company News
Jan. 24 Company Quick Takes: Tecentriq misses in bladder cancer; plus Gilead-CDC and PureTech
Items per page:
1 - 10 of 35